Form 4: Xenon Pharmaceuticals Director Elizabeth Garofalo Receives Significant Equity Compensation

Xenon Pharmaceuticals Inc. Director Elizabeth A. Garofalo was granted 17,012 stock options and 2,645 restricted share units as part of her compensation, aligning her interests with shareholders.

Summary

• Elizabeth A. Garofalo, a Director of Xenon Pharmaceuticals Inc. (XENE), reported the acquisition of derivative securities on June 5, 2025.
• She was granted 17,012 share options with an exercise price of $30.73 per share.
• Additionally, she received 2,645 Restricted Share Units (RSUs).
• Both the share options and RSUs are scheduled to vest 100% on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders.
• The share options have a long-term expiration date of June 4, 2035.
• Following these transactions, Ms. Garofalo beneficially owns 17,012 share options and 2,645 Restricted Share Units directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a routine grant of equity compensation to a director, aligning their interests with shareholders. This is a standard practice and generally viewed favorably as it incentivizes long-term performance and retention of key board members.

Positives

• The grant of stock options and restricted share units to a director aligns management and board interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector, demonstrating commitment to governance.

Negatives

• No negative aspects are indicated in this routine equity compensation filing; it represents a standard form of director remuneration.

Future Outlook

The granted share options and restricted share units are set to vest on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting, indicating future equity realization for the director and a continued alignment of interests.

Industry Context

Equity compensation, including stock options and restricted share units, is a prevalent practice in the biotechnology and pharmaceutical industries to compensate directors and executives. This approach is designed to align the interests of company leadership with long-term shareholder value creation, which is particularly critical in a sector characterized by long development cycles and significant R&D investments.

Comparison to Industry Standards

• The grant of equity compensation to a director is a standard practice across publicly traded companies, particularly within the biotechnology sector.
• This type of compensation is generally in line with industry norms for non-employee directors, aiming to incentivize performance and retention.
• Without specific peer group compensation data for companies like Biogen, Vertex Pharmaceuticals, or Sarepta Therapeutics, a direct quantitative comparison of the grant size is not feasible, but the mechanism itself is standard.

Related Party Transactions

• The grant of equity compensation (share options and restricted share units) to Elizabeth A. Garofalo, a Director of Xenon Pharmaceuticals Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors, which is a common and disclosed practice for director compensation.

Stakeholder Impact

• **Shareholders:** The equity grants align the director's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price and overall company performance.
• **Employees:** While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel and maintaining a competitive compensation framework.
• **Creditors:** No direct impact on creditors from this specific transaction, as it relates to equity compensation rather than debt or operational cash flow.

Next Steps

• Vesting of the granted share options and Restricted Share Units on the earlier of June 4, 2026, or the day before the issuer's 2026 annual meeting of shareholders, at which point the director will gain full ownership rights.

Key Dates

Recommendation

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Share Units, Director Compensation, Beneficial Ownership, Biotechnology